NASDAQ:HLVX HilleVax (HLVX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free HLVX Stock Alerts $12.58 -0.23 (-1.80%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$12.47▼$12.8450-Day Range$11.86▼$19.7552-Week Range$9.94▼$20.22Volume49,066 shsAverage Volume136,363 shsMarket Capitalization$625.48 millionP/E RatioN/ADividend YieldN/APrice Target$30.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get HilleVax alerts: Email Address HilleVax MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.8% Upside$30.67 Price TargetShort InterestHealthy2.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 3 Articles This WeekInsider TradingSelling Shares$986.46 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.22) to ($3.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.70 out of 5 starsMedical Sector227th out of 907 stocksBiological Products, Except Diagnostic Industry32nd out of 153 stocks 3.5 Analyst's Opinion Consensus RatingHilleVax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHilleVax has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.90% of the float of HilleVax has been sold short.Short Interest Ratio / Days to CoverHilleVax has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HilleVax has recently decreased by 5.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHilleVax does not currently pay a dividend.Dividend GrowthHilleVax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HLVX. Previous Next 3.3 News and Social Media Coverage News SentimentHilleVax has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for HilleVax this week, compared to 1 article on an average week.Search Interest1 people have searched for HLVX on MarketBeat in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HilleVax insiders have sold 659,521.69% more of their company's stock than they have bought. Specifically, they have bought $149,550.00 in company stock and sold $986,464,242.00 in company stock.Percentage Held by Insiders29.30% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.42% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for HilleVax are expected to decrease in the coming year, from ($3.22) to ($3.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HilleVax is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HilleVax is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHilleVax has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About HilleVax Stock (NASDAQ:HLVX)HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Read More HLVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLVX Stock News HeadlinesApril 9, 2024 | insidertrades.comInsider Buying: HilleVax, Inc. (NASDAQ:HLVX) Major Shareholder Buys 8,850 Shares of StockApril 7, 2024 | insidertrades.comAditya Kohli Sells 6,000 Shares of HilleVax, Inc. (NASDAQ:HLVX) StockApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 2, 2024 | insidertrades.comSean Mcloughlin Acquires 1,250 Shares of HilleVax, Inc. (NASDAQ:HLVX) StockApril 18, 2024 | americanbankingnews.comHilleVax, Inc. (NASDAQ:HLVX) Short Interest Down 5.6% in MarchApril 7, 2024 | investing.comHillevax director Aditya Kohli sells shares worth over $264kMarch 22, 2024 | seekingalpha.comHilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued ValuationMarch 21, 2024 | markets.businessinsider.comHilleVax, Inc’s HIL-214 Vaccine Candidate Promises Broad Protection Against Norovirus, Justifying Buy RatingApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 20, 2024 | benzinga.comRecap: HilleVax Q4 EarningsMarch 20, 2024 | finance.yahoo.comHilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company ProgressMarch 20, 2024 | globenewswire.comHilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 26, 2024 | msn.comJanux stock soars 96% in after hours trading on updated drug dataFebruary 23, 2024 | finance.yahoo.comDirector Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX)February 13, 2024 | benzinga.comAditya Kohli's Net WorthFebruary 5, 2024 | finance.yahoo.comHilleVax to Present at Guggenheim 6th Annual Biotechnology ConferenceJanuary 18, 2024 | markets.businessinsider.comHilleVax Appoints GSK's Sean McLoughlin As COOJanuary 18, 2024 | finance.yahoo.comHilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating OfficerJanuary 8, 2024 | finance.yahoo.comHilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of ChinaJanuary 5, 2024 | benzinga.comHilleVax Stock (NASDAQ:HLVX) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comHilleVax to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 19, 2023 | finance.yahoo.comInsider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 10,000 Shares of HilleVax Inc ...December 14, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of HilleVax (HLVX) with Buy RecommendationDecember 6, 2023 | finance.yahoo.comInsider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 20,000 Shares of HilleVax Inc ...November 30, 2023 | finance.yahoo.comWall Street Analysts Believe HilleVax, Inc. (HLVX) Could Rally 92.19%: Here's is How to TradeNovember 14, 2023 | finance.yahoo.comHilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the UpgradeNovember 14, 2023 | finance.yahoo.comDoes HilleVax, Inc. (HLVX) Have the Potential to Rally 107.23% as Wall Street Analysts Expect?See More Headlines Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today4/24/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:HLVX CUSIPN/A CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$30.67 High Stock Price Target$34.00 Low Stock Price Target$28.00 Potential Upside/Downside+143.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,570,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-48.17% Return on Assets-38.05% Debt Debt-to-Equity Ratio0.10 Current Ratio10.62 Quick Ratio10.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.48 per share Price / Book2.30Miscellaneous Outstanding Shares49,720,000Free Float35,153,000Market Cap$625.48 million OptionableNot Optionable Beta0.65 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Robert M. Hershberg M.D. (Age 62)Ph.D., President, CEO & Chairman of the Board Comp: $1.02MDr. Aditya Kohli Ph.D. (Age 35)Chief Business Officer & Director Comp: $782.44kMr. Shane A. Maltbie (Age 42)CFO & Treasurer Mr. Sean McLoughlin (Age 52)Chief Operating Officer Dr. Anju Chatterji Ph.D.Chief Technology OfficerMr. Paul S. Bavier J.D. (Age 52)General Counsel, Secretary & Chief Administrative Officer Ms. Astrid Borkowski M.D. (Age 54)Ph.D., Chief Medical Officer Mr. Ozzie BergerSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsCabaletta BioNASDAQ:CABAMesoblastNASDAQ:MESONovavaxNASDAQ:NVAXProKidneyNASDAQ:PROKPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsAditya KohliSold 6,000 sharesTotal: $86,640.00 ($14.44/share)Life Sciences X L.P. FrazierBought 8,850 shares on 4/4/2024Total: $128,325.00 ($14.50/share)Aditya KohliSold 6,000 sharesTotal: $89,580.00 ($14.93/share)Sean McloughlinBought 1,250 shares on 3/28/2024Total: $21,225.00 ($16.98/share)Aditya KohliSold 6,000 sharesTotal: $985.33 M ($164,221.00/share)View All Insider TransactionsView All Institutional Transactions HLVX Stock Analysis - Frequently Asked Questions Should I buy or sell HilleVax stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HLVX shares. View HLVX analyst ratings or view top-rated stocks. What is HilleVax's stock price target for 2024? 3 brokers have issued twelve-month target prices for HilleVax's stock. Their HLVX share price targets range from $28.00 to $34.00. On average, they anticipate the company's share price to reach $30.67 in the next year. This suggests a possible upside of 143.8% from the stock's current price. View analysts price targets for HLVX or view top-rated stocks among Wall Street analysts. How have HLVX shares performed in 2024? HilleVax's stock was trading at $16.05 at the beginning of the year. Since then, HLVX stock has decreased by 21.6% and is now trading at $12.58. View the best growth stocks for 2024 here. Are investors shorting HilleVax? HilleVax saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 448,200 shares, a decline of 5.6% from the March 15th total of 474,900 shares. Based on an average trading volume of 124,700 shares, the days-to-cover ratio is presently 3.6 days. Currently, 2.9% of the company's stock are short sold. View HilleVax's Short Interest. When is HilleVax's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our HLVX earnings forecast. How were HilleVax's earnings last quarter? HilleVax, Inc. (NASDAQ:HLVX) issued its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.02. What ETFs hold HilleVax's stock? ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).Morningstar US Small Growth (MSGR). When did HilleVax IPO? HilleVax (HLVX) raised $200 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share. How do I buy shares of HilleVax? Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HLVX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
